Funder
Janssen Scientific Affairs, LLC
Publisher
Springer Science and Business Media LLC
Reference41 articles.
1. Ramirez-Fort MK, Levin AA, Au SC, Gottlieb AB. Continuous versus intermittent therapy for moderate-to-severe psoriasis. Clin Exp Rheumatol. 2013;31(4 Suppl 78):S63-70.
2. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–60.
3. Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–72.
4. Gisondi P, Del Giglio M, Girolomoni G. Treatment approaches to moderate to severe psoriasis. Int J Mol Sci. 2017;18(11):2427.
5. Center for Drug Evaluation and Research U.S. Food and Drug Administration. Alefacept Product Approval Information - Licensing Action 2003. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2003/alefbio013003L.htm. Accessed Aug 13, 2019.
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献